During development enhancers play pivotal roles in regulating gene expression programs; however, their involvement in cancer progression has not been fully characterized. We performed an integrative analysis of DNA methylation, RNA-seq and small RNA-seq profiles from thousands of patients, including 25 diverse primary malignances and 7 body sites of metastatic melanoma. We found that enhancers are consistently the most differentially methylated regions (DMR) as cancer progress from normal to primary tumors and then to metastases, compared to other genomic features. Remarkably, identification of enhancer DMRs (eDMRs) enabled classification of primary tumors according to physiological organ systems and in metastasis eDMRs are the most correlated with patient outcome. To further understand eDMR role in cancer progression we developed a model to predict genes and microRNAs that are regulated by enhancer and not promotor methylation, which shows high accuracy with chromatin architecture methods and was experimentally validated. Interestingly, among all metastatic melanoma eDMRs the most correlated with patient survival were eDMRs that 'switched' their methylation patterns back and forth between normal, primary and metastases and target cancer drivers, e.g.: KIT.
INTRODUCTION
The landscape of DNA methylation undergoes global changes in many cancers (Jones 2012) which contribute to genomic instability (Pogribny and Beland 2009), facilitate genetic mutations (You and Jones 2012) , and alter gene expression programs (Easwaran et al. 2014) . Most studies of DNA methylation changes in cancers have focused on promoter regions, since hypermethylation of promoters is a key mechanism for gene silencing (Esteller 2007) . Less attention has been given to aberrant DNA methylation in other region of the genome, such as enhancers Marzese et al. 2013; Ziller et al. 2013; Brocks et al. 2014) , and to its influence on gene expression in cancer.
During development enhancers play pivotal roles in regulating expression programs , are characterized by tissue-specific chromatin marks (Heintzman et al. 2009 ), and their activation corresponds with nucleosome and methylation loss (Zhou et al. 2011; Buecker and Wysocka 2012; Taberlay et al. 2014) . Recent studies have used these features to predict enhancer-gene interactions Andersson et al. 2014; Aran and Hellman 2014; He et al. 2014 ); however, these methods provide limited insight into the roles of enhancers in cancer, in particularly, the transcriptional consequences of abnormal enhancer methylation.
Cancer plasticity refers to the ability of tumor cells to transition between states and evolve under selective pressure, facilitating metastagenesis (Friedl and Alexander 2011; Tam and Weinberg 2013) . Tumor heterogeneity and the microenvironment clearly impact cancer cell plasticity (Friedl and Alexander 2011; Brabletz 2012; Meacham and Morrison 2013) . However, unlike genetic mutations, DNA methylation is a reversible modification, (Franchini et al. 2012) , thus, we hypothesized that methylation changes could promote cancer progression by affecting cancer cell plasticity. To test this hypothesis, we extended the analysis of (Aran and Hellman Cold Spring Harbor Laboratory Press on April 6, 2016 -Published by genome.cshlp.org Downloaded from 2013; Aran and Hellman 2014) and analyzed differential DNA methylation patterns in twenty five cancer types and seven sites of metastatic melanoma. Our analysis suggests that enhancer methylation changes can be indicative of patient outcome, and may contribute to cancer progression through cancer cell plasticity.
RESULTS

Enhancers exhibit highly dynamic methylation patterns upon malignant transformation
In order to methodically examine DNA methylation changes involved in malignant transformation we analyzed 23 distinct cancer types (overall 25 datasets). We used the genome-wide scale Illumina HumanMethylation450 arrays (Dedeurwaerder et al. 2011 ) to identify differentially methylated regions (DMRs) by analyzing over 6200 DNA methylation profiles of patients' tumor and normal tissue (Supplemental Table   S1 ). We identified 123,649 DMRs (minimum region-wise mean methylation difference >0.3, false discovery rate, q<0.2). Interestingly, we found that enhancers had more DMRs than any other genomic region; promoters and CpG islands exhibited the less variation (Fig. 1A) . This result suggests that alterations of enhancer methylation have a significant role in cancer progression, in support of data reported previously Ziller et al. 2013; Aran and Hellman 2014; Taberlay et al. 2014) .
To test whether the selected threshold of 0.3 for differential methylation represented an optimal measure, we calculated the fraction of DMRs in each genomic feature using higher and lower thresholds (from 0.2 to 0.5); enhancers were consistently the most variable regions (Supplemental Fig. S1A ). As the frequency of CpG dinucleotides varies with genomic features (Supplemental Fig. S1B ), we repeated the differential methylation analysis using methylation levels of individual CpG sites in the array (Supplemental Fig. S1C ), and observe consistent results, namely that CpG Cold Spring Harbor Laboratory Press on April 6, 2016 -Published by genome.cshlp.org Downloaded from methylation within enhancers are the most variable compared to all other genomic features.
Given the parallels between embryonic development and oncogenic transformation (Hon et al. 2013) , we examined the binding patterns of central pluripotent transcription factors (TFs) POU5F1, SOX2, and NANOG in various DMRs. We observed that multiple binding occurred more frequently at differentially methylated enhancers than at promoters or CpG islands (Fig. 1B) . These results support previous findings (Göke et al. 2011; Whyte et al. 2013) suggesting that eDMRs bound by pluripotent TFs may mediate central expression programs. To qualitatively examine the altered enhancers, we analyzed information on ChromHMM states (Ernst and Kellis 2012) . We found that compared to enhancers that were not differentially methylated (static enhancers), eDMRs were significantly enriched for the ChromHMM state of 'strong enhancers' (P<2e-16, Fig. 1C ), similar to previous reports ). This results suggest that enhancers altered in cancer, may regulate their target genes more strongly than do unaltered enhancers. It is known that promoter and island hypermethylation are associated with gene silencing in cancers (Bergman and Cedar 2013) , and, indeed, we found that these regions were frequently hypermethylated (63% and 94%, respectively). In comparison, enhancers were mostly differentially hypomethylated (67%, Fig. 1D ). Next, used chromatin marks to qualitatively determine the chromatin features of the hypermethylated and hypomethylated enhancers. Using data from the ENCODE Project (Rosenbloom et al. 2013) , we found that differentially hypomethylated enhancers exhibited significantly higher levels of chromatin marks of active DNA (increased DNase I, H3K4me1, H3K4me2, H3K27ac, H2A.Z, EP300, POL2, and decreased CTCF).
Whereas, differentially hypermethylated enhancers showed the footprints of closed and inactive DNA ( Fig. 1E and Supplemental Fig. S1D -E), consistent with previous results (Zhou et al. 2011; Lam et al. 2014) . Taken together, the Cold Spring Harbor Laboratory Press on April 6, 2016 -Published by genome.cshlp.org Downloaded from analysis of multiple tumor types strongly suggests that alteration of enhancer methylome is a frequent feature of transformed cells, and that it generally leads to chromatin activation, likely involved in cancer progression.
Differential methylation patterns of eDMRs clusters tumors according to their organ system
Next, we compared the patterns of methylation change in enhancers between the various types of cancer. Since enhancers show tissue-specific patterns of histone modifications and TF binding in normal cells (Bulger and Groudine 2011) , we expected that alteration of methylation patterns would be cancer/tissue-specific.
Indeed, most eDMRs (54%) were unique to a single cancer type ( Fig. 2A) . Strikingly, principal components analysis (PCA) of eDMRs showed a higher order clustering of cancers into groups related to the same organ system (Fig. 2B ). For example, the central nervous system cluster includes cancers arising from glia and astrocytes (Fig.   2B , green circle); similarly, the reproductive system cluster consists of breast, uterine, and prostate tumors (Fig. 2B, pink circle) . Importantly, PCA analyses of differentially methylated islands, promoters, and intergenic regions showed no such clustering (Supplemental Fig. S2A-C) . No library preparation batch affect was found, either (Supplemental Fig. S2D-E) . This evidence provides confidence that our findings were not affected by batch effect, and strengthen our hypothesis that enhancer methylation changes may have meaningful biological roles.
Next, in order to uncover the functional effect of altered enhancer methylation, we first compared the genomic neighborhood of eDMRs with static enhancers (those showing no differential methylation). We found that eDMRs were flanked by more genes and microRNA (miRNA) than were static enhancers (Supplemental Fig. S2F -G). To identify which genes the eDMRs regulate, we developed an integrated model Cold Spring Harbor Laboratory Press on April 6, 2016 -Published by genome.cshlp.org Downloaded from combining multi-omics data for associating enhancers with their target genes (eDMRassociated genes) ( Fig. 2C and Supplemental Fig. S2H for pipeline). Since it is known that there is an inverse correlation between DNA methylation and chromatin activity (Zhou et al. 2011) , we retained only inversely correlated eDMR-gene pairs, which represented the majority of our data (Supplemental Fig. S2I ). In order to assess the validity of our eDMR-gene pair predictions, we compared our results to other methods that identify enhancer-promotor associations based on physical interactions IM-PET (He et al. 2014) , ChIA-PET, Hi-C (Teng et al. 2015) , and transcriptional activities of interacting enhancer-promoters (cap analysis gene expression. CAGE) (Andersson et al. 2014) . Our model predicted eDMR-gene pairs separated by 400 kb or less at a precision rate of 75% or better (Fig. 2D) , indicating that our model can reliably predict interacting enhancer gene pairs.
Similar to their enhancers (Fig. 2B) , the genes predicted to be regulated by the eDMRs, also showed organ system patterns of enrichment (Fig. 2E , Supplemental Table S3 ). Using our model we were identify known tissue-specific and ubiquitous oncogenic genes and microRNAs (miRNAs) (Fig. 2F-H ), such as: ESR1 in breast cancer (Holst et al. 2012; Aran and Hellman 2014) , ECT2 in lung cancer (Murata et al. 2014) , and WNT3A in prostate cancer (Verras et al. 2004 ), hsa-miR-9-1 (Ma et al. 2010 ) and the clustered miRNAs hsa-miR-200a and miR-200b (Korpal et al. 2008 ) (see Supplemental Table S4 for full list of predicted eDMR-gene pairs).
Taken together, our model defines cancer-related eDMRs as organ-system-specific regulators of genes and miRNAs that are central to malignant transformation. Our analysis showed that changes in methylation patterns of enhancers in primary tumor tissues are influenced by their relation to the organ system (Fig. 2B ), we were curious what would occur to DNA methylation patterns of cells that disseminate from the primary location, and colonize in metastatic sites. To evaluate this, we focused on melanoma, a highly metastatic cancer (Braeuer et al. 2014) . We compared methylation data from metastatic melanoma patients (7 distinct locations) to data from patients with primary in situ melanoma (Supplemental Table S1 ). Consistent with our observation of differential methylation patterns in primary tumors (Fig. 1A) , the majority of 'metastatic DMRs' occurred within enhancers (Fig. 3A) , suggesting that enhancers play important roles, not only in malignant transformation, but also in metastatic progression. Additionally, metastatic eDMRs much better differentiate between patient outcomes than do DMRs from any other genomic feature ( Fig. 3B and Supplemental Fig. S3A ). The majority of eDMRs were specific to a single metastatic site ( Fig. 3C and Supplemental Fig. S3B ), and were mostly (74%) hypomethylated (Fig. 3D ), similar to our observations in primary cancers (see Fig. 2A and Fig. 1D ). Strikingly, Fig. 3E shows that accumulation of hypomethylated enhancers highly correlates with the likelihood of forming metastases at distant organs (derived from (Meyers and Balch 1998) ). For example, melanoma is more likely to metastasize to lymph nodes than to the brain, correspondingly, a greater number of enhancers are differentially hypomethylated in brain metastases than in lymph node metastases (2.24% and 0.33%, respectively; Fig. 3E ). In contrast, we found no correlation between the fraction of differentially hypermethylated metastatic eDMRs and the frequency of spreading to organs (Supplemental Fig. S3C ). These results are in agreement with studies suggesting that global hypomethylation is a common feature of diseased states (Pogribny and Beland 2009) . Since widespread DNA methylation changes are associated with aging (Richardson 2003) , we calculated the correlations between patient ages and accumulation of enhancers methylation changes. Encouragingly, we found no significant correlation between eDMR methylation changes in metastatic tissues and the patient age (Supplemental Fig. S3D ), suggesting that metastatic progression corresponds to cancer-related changes, and not age-related changes.
Accumulation of eDMR hypomethylation correlates with likelihood of metastasis
In order to specifically explore whether melanoma eDMRs could promote metastatic growth, we identified genes differentially expressed between primary and metastatic melanoma, and compared the correlation of these genes with methylation patterns of differentially methylated enhancers and promoters (eDMRs and pDMRs, respectively). We found that eDMRs were significantly more correlated with differentially expressed genes than were pDMRs (Supplemental Fig. S3E ). Next, we divided the genes into two groups: eDMR-associated genes and all other genes not identified by our model to be associated with eDMRs (control genes, Fig. 3F ), and examined the differential expression patterns of these two groups. The percent of genes that were differentially expressed between normal and primary melanoma was similar for both groups (60% and 53% for eDMR-associated genes and control genes, respectively; Fig. 3F ), however, between primary and metastatic melanoma the eDMR-associated genes were significantly more variable than the control genes (binomial distribution, P<2e-16; 57% and 3% respectively, Fig. 3F , marked by gray areas). This observation supports our notion that a functional interaction exists between the eDMRs and their predicted associated genes. Additionally, we note that a fraction of the control genes were downregulated in both primary and metastatic melanoma ( (Fig. 4A , left circle). We examined whether these three groups of eDMR differed with respect to metastatic progression, by comparing their ability to correlate with survival of patients (see Methods). To our knowledge, this is one of the first examples (Stone et al. 2015 ) of a survival analysis applied to DNA methylation patterns of enhancers. We identified 30 eDMRs that were associated with patient survival rates (marked 'survival' eDMRs, Fig. 4A , middle circle). Remarkably, these survival eDMRs were enriched with the switched eDMRs ( Fig. 4A ), whereas de novo eDMRs were significantly depleted (Fig. 4A ). In addition, the switched eDMRs exhibited the highest conservation scores (Fig. 4B) , and the fewest copy number variations (CNVs) in melanoma patients (Fig. 4C ). These results suggest that eDMRs, in particular the switched eDMRs that exhibit methylation plasticity, are functionally important in cancer.
Given these results, we hypothesized that methylation plasticity may play important roles in melanoma metastatic progression. To examine this, we performed survival analyses also the eDMR-associated genes, using their expression patterns across patients. Remarkably, we found that 40% were able to significantly differentiate between survival outcomes (Chi-square, q<0.1, FDR corrected); these genes include: ATP2B1 (Lee et al. 2002) , FMNL2 (Zhu et al. 2008) , KIT (Tian et al. 1999) , PRKCE (Sharif and Sharif 1999) , and VGF (Mitra et al. 2008) . Figure To experimentally test the role of enhancer methylation on the transcriptional regulation of KIT, we first examined KIT expression upon treatment with 5-aza-2'-deoxycytidine (5-aza-dC), a DNA methyltransferase inhibitor. There was a significant decrease in KIT levels in treated compared with untreated cells (Fig. 4E ). Next, we cloned the KIT enhancer upstream of luciferase reporter, and demonstrated that its expression was reduced upon enhancer methylation ( Fig. 4F and Supplemental Fig.   S4A ). Finally, we examined the role of KIT upregulation on the invasive potential of melanoma cells (Fig. 4D) . Remarkably, noninvasive melanoma cells (Golan et al. 2015 ) acquired significant invasion ability upon KIT over-expression (Fig. 4G and Supplemental Fig. 4B) . Taken together, our data demonstrate that enhancer methylation contributes to cancer progression by directly regulating oncogene expression.
Next, we asked whether the dynamics of eDMR methylation and eDMR-associated genes expression are a result of tumor heterogeneity, evolution of the disseminated cancer cells, or are induced by the metastatic niche. To assess this, we selected two eDMR-associated genes, CTYL1 and KIF14, which were differentially expressed only between primary and metastatic melanoma (not between normal and primary melanoma tissues). CYTL1 is a cytokine-like protein implicated in lung cancer and neuroblastoma (Kwon et al. 2012; Wen et al. 2012) , and KIF14 is an oncogene essential for cytokinesis (Corson et al. 2005) ; both are upregulated in melanoma bone metastasis (P<0.05, Fig. 5A , top and bottom panels). High expression levels of these genes is correlated with poor patient survival rates (Fig. 5A , green stepwise curves; Chi-square q<0.1, FDR corrected). Enhancers of these genes were differentially methylated, yet their promoters were not ( Fig. 5A middle and right panels, respectively). To experimentally analyze the role of enhancer methylation on the transcriptional regulation of CYTL1 and KIF14, we first examined whether their expression is sensitive to DNA methylation. CYTL1 and KIF14 expression was significantly upregulated upon treatment of cells with 5-aza-dC (Fig. 5B) . Next, we cloned the identified enhancers of CYTL1 and KIF14 upstream to a luciferase reporter, and observed a decrease in the reporter expression upon enhancer methylation ( Fig. 5C and Supplemental Fig. S4A ). These results strengthen the validity of our model by demonstrating that the identified eDMRs, elicit response to changes in their methylation and directly regulate the expression of their associated genes: KIT, CYTL1, and KIF14. Finally, to assess changes in gene expression induced by metastatic melanoma cells colonization in the bone tissue, we first generated a melanoma cell line stably expressing the GFP gene, to enable tracking of the melanoma cells. Next, we established a co-culture of melanoma cells with human primary osteoblasts (Dillon et al. 2012) (Fig. 5D) , and found that levels of CYTL1 and KIF14 were significantly increased, compared to their levels in melanoma cells cultured alone (Fig. 5E ). Our data support the notion that homing into a new microenvironment induces expression of pro-cancer genes, which are regulated by eDMRs in melanoma metastatic cells. Taken together, our data suggest that methylation changes at enhancers contribute to melanoma phenotypic plasticity and ultimately to the patient's chance of survival.
DISCUSSION
Here we performed an analysis of DNA methylation alterations in over 6200 cancer patients from thirty-one cancer datasets, including twenty-three diverse primary malignant tumors, two benign tumors, and melanoma metastases to seven distinct organs. This extensive analysis revealed that most methylation variation occurs at enhancers (Fig. 1A, Fig. 3A and Supplemental Fig. S1C ). Changes in methylation patterns could result from competition between methylation and de-methylation processes or from errors in replication (Jones 2012) . Our findings support the latter hypothesis, for two reasons. First, replication-related methylation errors occur more frequently in methylated regions, such as enhancers, where replication errors lead to loss of methylation; this is what we observe (Fig. 1D) . Second, expression of DNMT3B, which encodes a methylase enzyme was upregulated in many tumors, and hence, we would expect increased methylation, since we observed no significant differences in expression of TET genes, which encode demethylase enzymes (Supplemental Fig. S2J ). However, since the majority changes in enhancers' methylation involves demethylation, we hypothesize that loss of enhancer methylation could have occurred during replication.
Enhancers play central roles in normal development and differentiation by responding to complex environmental cues. Cancer cells are exposed to changing environmental conditions that requires their adaptation; this mainly occurs through epigenetic reprogramming (Friedl and Alexander 2011; Goding et al. 2014) . We hypothesize that in the context of cancer, enhancer methylation may be primed to respond to microenvironmental signals. To test this, we mimicked the microenvironment of melanoma bone metastases, and recapitulated the perturbation of expression of eDMR-associated genes that were altered in the bone metastases.
These results suggest that the metastatic niche can alter expression of eDMRassociated genes.
Interestingly, we show that in comparison to DMRs in other genomic features (islands, promoter, exons, introns, etc.) eDMRs can differentiate best between patient outcomes (Supplemental Fig. S4D ). These results demonstrate the important role of alteration of enhancer methylation in cancer progression. However we do not exclude that other factors may drive cancer progression, nor are we suggesting a direct causality between enhancer methylation and cancer progression, it may well be that alteration of enhancer methylation is a secondary event of the malignancy.
Nevertheless, we did observe that methylation patterns of eDMRs may be informative of patient survival rates (Fig. 3B) . Within this group, was a subset (18%) of highly conserved eDMRs that displayed methylation plasticity ('switched' eDMRs, Fig. 4A-C) , and provided insight into alteration of their associated genes (Fig. 4D ). This is one of the first studies (Stone et al. 2015) to suggest that methylation patterns of enhancers can be used to predict patient outcome. Moreover, it is has been shown that in many diseases, including cancer, methylation changes are accumulative as the cancer progresses (Pogribny and Beland 2009 ); here we show that methylation plasticity may also play important roles in cancer progression (see Supplemental Fig.   S4C for model of methylation plasticity and cancer progression). A prime example of the relationships between metastatic progression, methylation plasticity, and patient mortality is that of the eDMR-associated oncogene, KIT (Fig. 4D-F) . Both the methylation of the eDMR and the expression of the KIT are display plasticity (Fig.   4D ), and significantly distinguish between patient survival rates. Our results suggest that enhancer methylation patterns may be informative of patient outcomes, and that they may influence malignant progression via methylome plasticity. 
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Chromatin marks, transcription factors (TFs), sequence conservation and copy number variation data
For analysis of chromatin marks ( Fig. 1E and Supplemental Fig. 1D-E Table S2 for ENCODE Project cell types.
For the transcription factor analysis (Fig. 1B) , we downloaded processed ChIP-seq data of POU5F1, SOX2, and NANOG downloaded from NCBI/GEO (GSE46130).
Replicate experiments were averaged. The TF peaks were overlapped with the coordinates of the differentially methylated enhancers, promoters, and islands.
For the conservation analysis of enhancer (Fig. 4B) we used 100-way PhastCons conservation data.
Copy number variations (CNVs) for skin cutaneous melanoma (SKCM) were obtained from the TCGA database as genomic segments after removal of germline CNV (TCGA_SKCM_GSNP6noCNV_gSeg).
Defining differentially methylated regions (DMRs)
First, we mapped the CpG codes in the Illumina HumanMethylation450 microarray to their genomic coordinates using the microarray platform (NCBI/GEO record GPL13534; human genome release hg19/GRCh37. Second, we annotated the CpGs using the information in this record, identifying CpG sites belonging to islands, shores, shelves, enhancers and UTRs. Given that this record does not have information of CpG sites in promoters, exons or introns, we used the UCSC table 'knownGene' to identify these sites. Third, some CpG sites had several annotations, thus, we divided the CpGs into unique (non-overlapping) genomic features using the following prioritization: 1) promoters, 2) islands, 3) enhancers, 4) introns, 5) exons, 6) UTRs, 7) shores, 8) shelves and 9) intergenic regions. Fourth, for each separate genomic feature we constructed intervals using a window of 500 bp directly upstream and downstream of the CpG coordinate. Overlapping intervals (same genomic feature) were joined, and extended into a larger interval. 69% of the regions had a length of 1000 bp, 28% a length greater than 1000 bp and less than 2000 bp, no region was greater in length than 7500 bp. Fifth, we used these genomic intervals to calculate region-wise methylation levels based on the average methylation of all CpG sites within the interval, we performed this for all normal and all tumor samples in each cancer dataset. Sixth, we used the two-sample Wilcoxon test to identify differentially methylated regions (DMRs) between normal and primary samples (methylation threshold >0.3, q<0.2, FDR corrected); metastatic DMRs were identified by comparing primary and metastatic melanoma (methylation threshold >0.2 and q<0.2). The fractions of DMRs in each genomic feature presented in Fig. 1A, Fig. 3A and Supplemental Fig. S1C were normalized to the amount of intervals in each genomic feature in the Illumina HumanMethylation450 array (Dedeurwaerder et al. 2011 ).
Gene and miRNA differential expression analysis
A fold-change of 1.25 was used to determine differentially expressed genes and miRNAs (q<0.05, FDR corrected; see Supplemental Methods for description).
Model for prediction of gene-eDMR associations
We developed an integrated model to predict genes or miRNAs regulated by eDMRs ( Fig. 2C and flowchart in Supplemental Fig. S2H ). First, we calculated the differential methylation in enhancer and promoter regions, retaining the eDMRs, and using the level of promoter methylation change in the third step. Second, we computed Spearman's correlations between eDMR methylation patterns and gene/miRNA expression patterns across the same (matched) patients. Highly correlated eDMRgenes or eDMR-miRNAs pairs were retained (negative correlation below -0.4). Third, we filtered out genes for which promoter differential methylation was greater than 0.2, enriching for genes with expression change due to enhancer, rather than by promoter, methylation variability (performed only for predicting eDMR-associated genes and not associated-miRNAs, since annotation for miRNA promoters is incomplete). Fourth, we selected eDMR-gene and eDMR-miRNA pairs located on the same chromosome, with a maximal linear distance of 1 Mbp between the center of the enhancer and the transcription start site (for genes) or pre-miRNA start position (for miRNAs). Fifth, we ranked eDMR-gene predictions (see Supplemental Table S4 and section Ranking eDMR-gene pairs predictions).
Ranking eDMR-gene pairs predictions
In order to provide confidence that the predicted eDMR-gene pairs represent active enhancer-gene interactions, we applied an integrated scoring function. Our scoring scheme combined quantitative and qualitative features of the eDMR-gene pairs. promoter overlap with H3K4me3 or DNase I peaks. We summed up the scores for each eDMR-gene pairs (ties were given an average ranking score), sorted them based on their overall score, yielding ranked predictions (Supplemental Table S4 ).
Gene enrichment analysis for diseases
We used the DISEASES website (http://diseases.jensenlab.org) (Pletscher-Frankild et al. 2014) to evaluate enrichment for diseases in particular organ systems (Fig. 2E ).
Diseases were identified using keywords: digestive (digest-, gastro-, gastric, stomach), endocrine (endocrine-, gland disease, gland cancer, gland neoplasm, thyroid, pancreas), renal (kidney, renal, nephron-, nephri-), reproductive (reproduct-, breast, prostate, uterine, cervic-, cervix, uterus) , respiratory (lung, respirator); duplicate genes were removed to ensure unique values for hypergeometric distribution significance testing and FDR corrected.
Survival analysis
Survival time was derived from the 'overall survival' column of the clinical data files obtained for TCGA samples. First, patients were divided into two groups (high and low) by comparing the eDMR methylation level to the median methylation the eDMR across all patients. Similarly, for gene expression survival analysis, patients were divided into two groups by comparing to the median expression of gene across all patients. Significant differences between the two groups were determined using the Chi-squared distribution (q<0.1, FDR corrected).
Enrichment for association of DMRs with patient survival (Fig. 3B) was determined by comparing the amount of DMRs that can significantly differentiate between patient outcomes, with the amount of static regions that can do the same (determined separately for each genomic feature).
Multiple testing
All significance tests were corrected for false discovery rates (FDR) using the Benjamini & Hochberg adjustment (Benjamini and Hochberg 1995) .
Computational data analysis
Data analyses were performed using R statistical language (R Core Team 2015). We used the following packages for R in the analysis 'GenomicRanges' (version 1.16.4) (Lawrence et al. 2013) , 'TxDb.Hsapiens.UCSC.hg19.knownGene' (version 3.1.2) (Carlson 2015) , 'survival' (version 2.37-7) (Therneau 2015) and 'reshape2' (version 1.4.1) (Wickham 2007) . Custom R scripts for determining differentially methylation regions, predicting and ranking eDMR-gene pairs are provided, together with a sample datasets derived from the TCGA are available in the Supplemental data (see 'INFO_README.txt' file).
Primary human osteoblasts and melanoma cells co culture
Primary human osteoblasts were isolated using a protocol described by Dillon et al. (Dillon et al. 2012) . In short, trabecular bone was obtained from healthy donors undergoing total knee arthroplasty. Written and informed consent was obtained from all subjects. The protocol was approved by the institutional Ethics Committee at TelAviv Sourasky Medical Center, in accordance with the Helsinki Declaration on the use of human subjects in research. The trabecular bone fragments were diced into small pieces and washed with sterile PBS. The diced bone extracts were then placed on a tissue culture plate with Dulbecco's Modified Eagle Medium (DMEM) supplemented with 20% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin (all from GIBCO, Life Technologies) and incubated at 37 °C and 5% CO 2 . Five days later, the medium was replaced; medium was then replaced twice a week until the cells reached confluency. Osteoblasts were then seeded 24 hour prior to addition of melanoma cells in a ratio of 1:5 melanoma cells to osteoblasts). In control plates, only melanoma cells were seeded. 
Cell culture and FACS sorting
RNA purification and qRT-PCR
Total RNA was purified from sorted melanoma cells using TRIzol (Invitrogen) according to manufacturer's instructions followed by treatment with RNase-free DNase (QIAGEN). RNA was quantified based on OD 260/280 . For qRT-PCR analysis RNA was subjected to one-step qRT-PCR using a MultiScribe RT-PCR kit (Applied Biosystems) and FastStart Universal SYBR Green Master Mix (Roche).
Plasmids and cloning
EDMRs of the human KIT, CYTL1, and KIF14 loci (Chr4:55708294-55709294, Chr1:201198480-201199526, Chr4:5019645-5020678, respectively) were amplified from human genomic DNA (see Supplemental Table S5 for 
In vitro methylation, transfections and dual luciferase assay
The KIT, CYTL1, and KIF14 eDMR firefly luciferase reporter vectors were in vitro methylated using the methylase SssI (New England Biolabs), according to manufacturer's recommendations, followed by purification using Wizard SV PCR clean-up system (Promega). Successful methylation was verified by restriction enzyme digestion with the methylation-sensitive (HpaII) and methylation-insensitive (MspI) enzymes and (New England Biolabs). The digestion patterns were analyzed by agarose gel electrophoresis. WM3682 melanoma cell lines were co-transfected using jetPEI™, with methylated eDMR-luciferase reporter plasmid, unmethylated reporter, or reporter plasmid without eDMR (as control) and with pRL-plasmid (Promega). Luciferase activity was measured 48 hours after transfection using Dual Luciferase kit (Promega). Firefly luciferase activity was normalized to the Renilla luciferase.
Invasion assay
WM3682 melanoma cell lines were transfected with KIT expression vector or empty vector (as control) using jetPEI™. 48 hours post transfection invasion assay was performed as previously described (Golan et al. 2015) . 
5-aza-deoxycytidine treatment
